Drug concentration at the site of disease in children with pulmonary tuberculosis.

Journal:

The Journal of antimicrobial chemotherapy, Volume: 77, Issue: 6

Published:

May 29, 2022

PMID:

35468189

Authors:

Elisa Lopez-Varela E, Ahmed A Abulfathi AA, Natasha Strydom N, Pierre Goussard P, Abraham C van Wyk AC, Anne Marie Demers AM, Anneen Van Deventer AV, Anthony J Garcia-Prats AJ, Johannes van der Merwe J, Matthew Zimmerman M, Claire L Carter CL, Jacques Janson J, Julie Morrison J, Helmuth Reuter H, Eric H Decloedt EH, James A Seddon JA, Elin M Svensson EM, Rob Warren R, Radojka M Savic RM, Véronique Dartois V, Anneke C Hesseling AC

Access Paper

DOI: 10.1093/jac/dkac103

PMID: 35468189

Abstract:

Current TB treatment for children is not optimized to provide adequate drug levels in TB lesions. Dose optimization of first-line antituberculosis drugs to increase exposure at the site of disease could facilitate more optimal treatment and future treatment-shortening strategies across the disease spectrum in children with pulmonary TB.

Courtesy of the U.S. National Library of Medicine